查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999139

不孕症治療市場：按產品類型、治療類型、診斷和最終用戶分類－2026-2032年全球市場預測

Infertility Treatment Market by Product Type, Treatment Type, Diagnosis, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，生育治療市場價值將達到 65.8 億美元，到 2026 年將成長到 73 億美元，到 2032 年將達到 143 億美元，複合年成長率為 11.71%。

主要市場統計數據
基準年 2025 65.8億美元
預計年份：2026年 73億美元
預測年份 2032 143億美元
複合年成長率 (%) 11.71%

對醫學進步、病患行為改變和營運壓力如何重新定義醫療保健相關人員的生育治療優先事項進行策略概述。

在生育治療領域，臨床創新、患者人口結構的變化以及不斷發展的醫療保健服務模式相互交織，為醫療保健提供者、供應商和保險公司創造了機會和挑戰。

變革性的變化正在重新定義整個生育生態系統的臨床實踐、供應鏈韌性、以患者為中心的服務以及政策獎勵。

不孕症治療格局正在發生變化，這種變化同時改變了臨床實踐、供應鏈和護理模式。

本研究評估了美國近期關稅措施對生育治療價值鏈中的採購成本、供應鏈策略和臨床照護取得的影響。

美國最近採取的關稅措施為生育治療行業的製造商、經銷商和最終用戶帶來了新的成本和物流方面的考慮。

將產品類型、治療方法、診斷途徑和最終用戶畫像與營運重點和投資決策聯繫起來的細分市場主導洞察。

對市場區隔的詳細分析揭示了臨床需求、資本密集度和對耗材的依賴的交集，從而為相關人員創造了不同的策略挑戰。

區域趨勢分析揭示了人口趨勢、還款框架和當地能力如何影響主要全球市場的採用和取得。

區域趨勢影響全球生育治療市場的需求模式、監管方式和競爭地位。

透過模組化產品平台、策略夥伴關係和基於證據的價值提案，使企業策略和競爭行動成為市場領導。

從策略角度分析企業行為，可以揭示在創新、投資組合管理和產品上市時間執行方面存在的差異化方法，這些方法決定了競爭的未來。

為領導者提供切實可行的建議，以協調技術投資、供應鏈彈性、證據生成和以患者為中心的服務，從而獲得競爭優勢。

行業領導者可以透過協調其商業、臨床和營運策略，利用當前趨勢在患者就醫和治療效果方面取得可衡量的改進。

我們採用透明的混合方法研究途徑，結合一手訪談、二手檢驗和檢驗，提供可靠的產業洞察和策略指導。

本分析所依據的研究途徑結合了定性和定量方法，以確保調查方法的穩健性和透明性，從而得出可操作的結論。

摘要強調技術採用、供應彈性、證據產生和以病人為中心的服務模式的策略一致性。

總之，由於技術成熟、患者期望變化以及對供應鏈和政策的審查日益嚴格，生育生態系統正處於轉折點。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：不孕症治療市場：依產品類型分類

  • 配件
  • 裝置
    • 冷凍保存系統
    • 氣體分析儀
    • 影像系統
    • 培養箱
    • 雷射系統
    • 微型機械手臂系統
    • 顯微鏡
    • 卵子抽吸泵
    • 精子分析系統
    • 精子分離裝置
  • 文化媒體與消費品
    • 冷凍保存介質
    • 培養基

第9章：依治療類型分類的不孕症治療市場

  • 人工授精
    • 子宮頸內人工授精
    • 輸卵管內人工授精
    • 子宮內人工授精
  • 輔助生殖技術（ART）
    • 胚胎冷凍保存
    • 體外受精（IVF）
    • 胞漿內單一精子注射（ICSI）
    • 胚胎著床前遺傳學診斷（PGD）
  • 不孕症藥物
    • 枸櫞酸氯米芬
    • 促性腺激素
    • 來曲唑
    • 二甲雙胍
  • 不孕症治療手術
    • 子宮鏡檢查
    • 腹腔鏡
    • 子宮肌瘤切除手術
    • 精索靜脈曲張修復
    • 精索靜脈曲張切除術

第10章：依診斷分類的不孕症治療市場

  • 女性不孕症
    • 造影（HSG）
    • 排卵測試
  • 男性不孕
    • 驗血
    • 精液分析
    • 睪丸切片檢查

第11章 不孕症治療市場：依最終使用者分類

  • 精子庫
  • 不孕症治療診所
  • 醫院
  • 研究機構

第12章 不孕症治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：不孕症治療市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 不孕症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國不孕症治療市場

第16章：中國不孕症治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bayer AG
  • City Fertility Centre
  • CooperSurgical, Inc.
  • Cryoport Systems, LLC.
  • Embryolab
  • Ferring International Center SA
  • FUJIFILM Irvine Scientific, Inc.
  • Genea Group
  • IVI AMERICA, LLC
  • Merck KGaA
  • Monash IVF
  • New Hope Fertility Clinic
  • Nova IVF Fertility
  • NOW-fertility SA
  • Ovum Woman and Child specialty Hospital
  • ReproTech LLC
  • Seegene, Inc.
  • TMRW Life Sciences, Inc.
  • Vitrolife Sweden AB
Product Code: MRR-3E32260F8122

The Infertility Treatment Market was valued at USD 6.58 billion in 2025 and is projected to grow to USD 7.30 billion in 2026, with a CAGR of 11.71%, reaching USD 14.30 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.58 billion
Estimated Year [2026] USD 7.30 billion
Forecast Year [2032] USD 14.30 billion
CAGR (%) 11.71%

A strategic introduction to how clinical advances, patient behavior shifts, and operational pressures are redefining infertility treatment priorities across healthcare stakeholders

The infertility treatment landscape is experiencing a convergence of clinical innovation, shifting patient demographics, and evolving care delivery models that together create both opportunity and complexity for providers, suppliers, and payers.

Clinically, advances in laboratory instrumentation, cryopreservation protocols, and adjunctive therapeutics are enhancing cycle efficiency and expanding treatment options for previously refractory cases. At the same time, patient expectations are changing; greater awareness, delayed childbearing, and demand for individualized care pathways are prompting providers to broaden service offerings and invest in patient experience. Economically, resource allocation pressures and reimbursement variability require clinics and hospitals to balance capital investments in equipment and consumables with operational efficiency gains. As a result, stakeholders must align clinical priorities with pragmatic business models to sustain growth and deliver measurable outcomes.

Transformative shifts redefining clinical practice, supply chain resilience, patient-centric services, and policy incentives across the infertility treatment ecosystem

The landscape of infertility treatment is shifting in ways that are transforming clinical practice, supply chains, and care models simultaneously.

First, laboratory automation and digital imaging are accelerating throughput while improving consistency of embryology workflows; these technological shifts are prompting clinics to rethink staffing models and training priorities. Second, patient-centric trends such as expanded access to fertility preservation, elective oocyte freezing, and greater uptake of third-party reproduction are reshaping demand patterns and increasing the importance of integrated counseling and long-term follow-up services. Third, supply chain resilience has become a strategic priority: stakeholders are diversifying suppliers for key equipment, cryomaterials, and media to reduce vulnerability to single-source disruptions. Finally, regulatory and reimbursement environments are evolving, with payers and policymakers increasingly focused on value-based outcomes and equitable access, which will influence clinical protocols and investment decisions going forward.

Assessing how recent United States tariff measures influence procurement costs, supply chain strategies, and clinical access within the infertility treatment value chain

Recent tariff actions originating from the United States have introduced new cost and logistical considerations for manufacturers, distributors, and clinical end users in the infertility treatment sector.

Higher duties on imported laboratory equipment, specialized consumables, or component parts can increase landed costs for instruments such as incubators, microscopes, and cryosystems, as well as for culture media and cryopreservation reagents. In response, manufacturers may pursue localized assembly or alternative sourcing strategies to mitigate margin erosion. Clinicians and clinics, facing incremental cost pressures, may adjust procurement cycles, prioritize multi-use equipment, or renegotiate service contracts to preserve operating budgets. In parallel, distributors that historically aggregated international product lines may see shifts in product mix and lead times; they will need to enhance inventory planning and provide clearer total-cost-of-ownership analyses to customers.

Moreover, tariffs tend to accelerate technology substitution and supplier consolidation in the medium term. Domestic producers with existing capacity may gain negotiating leverage, while international suppliers may absorb some duty impacts to retain market presence, depending on competitive dynamics. Policymakers and industry associations will likely intensify dialogue around tariff exemptions for critical clinical supplies, and stakeholders should prepare to provide data-driven evidence of downstream effects on patient access and clinical outcomes. Ultimately, managing the cumulative impact of tariff policy requires coordinated procurement strategies, scenario planning, and clear communication across the supply chain to minimize disruption to patient care.

Segment-driven insights that connect product categories, treatment modalities, diagnostic pathways, and end-user profiles to operational priorities and investment choices

A nuanced view of market segmentation reveals where clinical demand, capital intensity, and consumable dependency intersect and create differentiated strategic imperatives for stakeholders.

When examining product type, equipment categories drive capital expenditure decisions: cryosystems, gas analyzers, imaging systems, incubators, laser systems, micromanipulator systems, microscopes, ovum aspiration pumps, sperm analyzer systems, and sperm separation devices each have distinct lifecycle, maintenance, and training requirements that affect clinic operating models and long-term budgeting. Accessories and media and consumables, including cryopreservation media and culture media, present recurring expense streams and influence vendor relationships and inventory management practices. From the treatment type perspective, delivery models vary considerably: artificial insemination modalities such as intracervical, intratubal, and intrauterine approaches contrast with assisted reproductive technologies that encompass embryo cryopreservation, in vitro fertilization, intracytoplasmic sperm injection, and preimplantation genetic diagnosis; fertility drugs-ranging from clomiphene citrate and letrozole to gonadotropins and metformin-introduce pharmacologic pathways and monitoring needs; and fertility surgeries such as hysteroscopy, laparoscopy, myomectomy, and varicocele interventions create distinct referrals and perioperative resource requirements. Diagnostic segmentation further clarifies care pathways: female infertility investigations rely on hysterosalpingography and ovulation testing, while male infertility assessment centers on blood tests, semen analysis, and testicular biopsy, each diagnostic route dictating laboratory priorities and patient counseling. Finally, end users-cryobanks, fertility clinics, hospitals, and research institutes-exhibit different procurement cycles, regulatory obligations, and expectations for service-level agreements. Taken together, this segmentation framework highlights where investment in specialized equipment, consumable supply security, workforce training, and patient education will deliver the greatest operational leverage.

Regional landscape analysis revealing how demographic trends, reimbursement frameworks, and local capabilities influence adoption and access across principal global markets

Regional dynamics shape demand patterns, regulatory approaches, and competitive positioning across the global infertility treatment landscape.

In the Americas, private clinic networks and an established reimbursement mix support high adoption of advanced assisted reproductive technologies and a sustained market for both specialized equipment and culture media. Conversely, Europe, Middle East & Africa presents heterogeneous regulatory and reimbursement landscapes where leading clinics drive innovation in urban centers while access variability persists across jurisdictions; this region also sees growing interest in fertility preservation and cross-border care. In the Asia-Pacific region, demographic trends including delayed parenthood and rising household incomes are expanding the patient base, driving rapid adoption of equipment and consumables, and prompting domestic manufacturers and international suppliers to adapt product offerings for affordability and scalability. Across all regions, transplantable best practices include investments in training, quality control, and cold-chain logistics for cryopreservation materials. Regional reimbursement policies, intellectual property regimes, and local manufacturing capacity will continue to be primary determinants of how quickly new technologies scale and how providers structure service portfolios.

Corporate strategies and competitive behaviors that differentiate market leaders through modular product platforms, strategic partnerships, and evidence-driven value propositions

A strategic read of company behavior underscores differentiated approaches to innovation, portfolio management, and go-to-market execution that will determine competitive trajectories.

Leading manufacturers increasingly prioritize modular equipment designs and platform-based consumable ecosystems to lock in long-term clinic relationships while offering upgrade pathways that protect customer investments. Service providers and clinic operators are consolidating or forming strategic alliances to achieve scale, standardize clinical protocols, and negotiate more favorable supply contracts. At the same time, entrants focused on single innovations-such as novel culture media formulations or AI-enabled imaging systems-seek partnership models with established distributors and laboratory networks to accelerate validation and adoption. Distribution firms are enhancing value-add services, including training, preventative maintenance, and total-cost-of-ownership analyses, to differentiate beyond price. Across the board, companies that invest in regulatory strategy, clinical evidence generation, and post-market real-world outcome tracking will secure competitive advantage by reducing adoption friction and demonstrating tangible benefits to clinicians and payers.

Actionable recommendations for leaders to align technology investments, supply resilience, evidence generation, and patient-centered services to secure competitive advantage

Industry leaders can capitalize on current trends by aligning commercial, clinical, and operational strategies to deliver measurable improvements in patient access and outcomes.

First, leaders should invest in scalable laboratory automation and training programs that increase throughput while preserving quality; by pairing equipment upgrades with standardized protocols and competency-based staff development, clinics can reduce cycle variability and improve cost efficiency. Second, firms should diversify supply chains and pursue nearshoring or dual-sourcing arrangements for critical consumables and instrument components to mitigate tariff and logistics risks; contracts that include contingency inventory provisions and transparent lead-time commitments will enhance resilience. Third, stakeholders must strengthen evidence generation by sponsoring robust clinical studies and real-world data initiatives that demonstrate comparative effectiveness and inform payer conversations; these data will be pivotal in advancing reimbursement discussions and broadening access. Finally, companies should expand patient-centric services-such as integrated counseling, long-term preservation offerings, and digital engagement tools-to differentiate care pathways and capture value across the patient lifecycle. Taken together, these actions will enable providers and suppliers to sustain growth while improving clinical reliability and patient satisfaction.

Transparent mixed-methods research approach integrating primary interviews, secondary validation, and triangulation to underpin reliable sector insights and strategic guidance

The research approach underpinning this analysis combined qualitative and quantitative techniques to ensure a robust and transparent methodology that supports actionable conclusions.

Primary research included structured interviews with clinicians, laboratory directors, procurement managers, and senior executives across device manufacturers and distributers to capture firsthand perspectives on clinical workflows, procurement priorities, and emerging pain points. Secondary research encompassed peer-reviewed clinical literature, regulatory filings, device manuals, and publicly available policy documents to validate technical performance characteristics and compliance considerations. Triangulation across data sources enabled cross-verification of claims, and methodological safeguards included standardized interview guides, coder-based synthesis of qualitative inputs, and sensitivity analyses for supply chain and policy impact scenarios. Where appropriate, industry terminology and segmentation frameworks were mapped to clinical pathways to ensure that product and treatment categories aligned with real-world practice. Limitations acknowledged in the methodology include variability in regional regulatory transparency and the evolving nature of tariff and reimbursement policies, which can introduce short-term uncertainty; nonetheless, the mixed-methods approach provides a defensible foundation for strategic planning and operational decision-making.

Concluding synthesis that emphasizes strategic alignment across technology adoption, supply resilience, evidence generation, and patient-focused service models

In conclusion, the infertility treatment ecosystem is at an inflection point driven by technological maturation, changing patient expectations, and heightened supply chain and policy scrutiny.

Stakeholders that proactively align investments in laboratory automation, workforce development, supply chain resilience, and evidence generation will be positioned to deliver higher-quality care at sustainable cost structures. Furthermore, differentiated patient-centric services and clear value communication to payers will be critical levers for expanding access and securing long-term demand. As regulatory and tariff landscapes evolve, agility in sourcing and strategic partnerships will determine which organizations can both protect margins and preserve clinical continuity. The combination of these dynamics creates opportunities for innovation across product development, clinical service models, and commercial execution, and it rewards those who translate technological advances into demonstrable improvements in patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infertility Treatment Market, by Product Type

  • 8.1. Accessories
  • 8.2. Equipment
    • 8.2.1. Cryosystems
    • 8.2.2. Gas Analyzers
    • 8.2.3. Imaging Systems
    • 8.2.4. Incubators
    • 8.2.5. Laser Systems
    • 8.2.6. Micromanipulator Systems
    • 8.2.7. Microscopes
    • 8.2.8. Ovum Aspiration Pumps
    • 8.2.9. Sperm Analyzer Systems
    • 8.2.10. Sperm Separation Devices
  • 8.3. Media & Consumables
    • 8.3.1. Cryopreservation Media
    • 8.3.2. Culture Media

9. Infertility Treatment Market, by Treatment Type

  • 9.1. Artificial Insemination
    • 9.1.1. Intracervical Insemination
    • 9.1.2. Intratubal Insemination
    • 9.1.3. Intrauterine Insemination
  • 9.2. Assisted Reproductive Technology (ART)
    • 9.2.1. Embryo Cryopreservation
    • 9.2.2. In Vitro Fertilization (IVF)
    • 9.2.3. Intracytoplasmic Sperm Injection (ICSI)
    • 9.2.4. Preimplantation Genetic Diagnosis (PGD)
  • 9.3. Fertility Drugs
    • 9.3.1. Clomiphene Citrate
    • 9.3.2. Gonadotropins
    • 9.3.3. Letrozole
    • 9.3.4. Metformin
  • 9.4. Fertility Surgeries
    • 9.4.1. Hysteroscopy
    • 9.4.2. Laparoscopy
    • 9.4.3. Myomectomy
    • 9.4.4. Varicocele Repair
    • 9.4.5. Varicocelectomy

10. Infertility Treatment Market, by Diagnosis

  • 10.1. Female Infertility
    • 10.1.1. Hysterosalpingography (HSG)
    • 10.1.2. Ovulation Testing
  • 10.2. Male Infertility
    • 10.2.1. Blood Tests
    • 10.2.2. Semen Analysis
    • 10.2.3. Testicular Biopsy

11. Infertility Treatment Market, by End User

  • 11.1. Cryobanks
  • 11.2. Fertility Clinics
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Infertility Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Infertility Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Infertility Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Infertility Treatment Market

16. China Infertility Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bayer AG
  • 17.6. City Fertility Centre
  • 17.7. CooperSurgical, Inc.
  • 17.8. Cryoport Systems, LLC.
  • 17.9. Embryolab
  • 17.10. Ferring International Center S.A.
  • 17.11. FUJIFILM Irvine Scientific, Inc.
  • 17.12. Genea Group
  • 17.13. IVI AMERICA, LLC
  • 17.14. Merck KGaA
  • 17.15. Monash IVF
  • 17.16. New Hope Fertility Clinic
  • 17.17. Nova IVF Fertility
  • 17.18. NOW-fertility SA
  • 17.19. Ovum Woman and Child specialty Hospital
  • 17.20. ReproTech LLC
  • 17.21. Seegene, Inc.
  • 17.22. TMRW Life Sciences, Inc.
  • 17.23. Vitrolife Sweden AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFERTILITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFERTILITY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INFERTILITY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INFERTILITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INFERTILITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFERTILITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOSYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOSYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOSYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GAS ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GAS ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GAS ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INCUBATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INCUBATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INCUBATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LASER SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LASER SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LASER SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROMANIPULATOR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROMANIPULATOR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROMANIPULATOR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROSCOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROSCOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROSCOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVUM ASPIRATION PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVUM ASPIRATION PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVUM ASPIRATION PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM ANALYZER SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM ANALYZER SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM ANALYZER SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM SEPARATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM SEPARATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM SEPARATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOPRESERVATION MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOPRESERVATION MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOPRESERVATION MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACERVICAL INSEMINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACERVICAL INSEMINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACERVICAL INSEMINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRATUBAL INSEMINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRATUBAL INSEMINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRATUBAL INSEMINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION (IVF), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION (IVF), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION (IVF), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION (ICSI), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION (ICSI), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION (ICSI), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS (PGD), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS (PGD), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS (PGD), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GONADOTROPINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GONADOTROPINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GONADOTROPINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LETROZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LETROZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LETROZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY METFORMIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY METFORMIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY METFORMIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MYOMECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MYOMECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MYOMECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELE REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELE REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELE REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY (HSG), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY (HSG), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY (HSG), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVULATION TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVULATION TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVULATION TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SEMEN ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SEMEN ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SEMEN ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TESTICULAR BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TESTICULAR BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TESTICULAR BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOBANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOBANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOBANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS INFERTILITY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA INFERTILITY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. GCC INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. GCC INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. GCC INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 274. GCC INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 275. GCC INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. GCC INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 277. GCC INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2018-2032 (USD MILLION)
  • TABLE 278. GCC INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 279. GCC INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2018-2032 (USD MILLION)
  • TABLE 280. GCC INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 281. GCC INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 282. GCC INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 283. GCC INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2018-2032 (USD MILLION)
  • TABLE 304. BRICS INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. G7 INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 311. G7 INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)